Structure Therapeutics Inc.
NASDAQ:GPCRBiotechnology
+$0.39 today
- Market cap
- $999.36M
- Beta
- -1.42
- P/E (TTM)
- -19.3
- EPS (TTM)
- -$2.35
Volume 1.10M
Average 0.87M
GPCR Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Structure Therapeutics Inc.NASDAQ: GPCR
Operating Expenses · Q2 FY2026 · quarter ended Jun 2026
Operating expenses growth accelerates
Q2 FY2026 operating expenses of $118.63M rose 68.4% year over year, ahead of the +16.9% change in trailing-twelve-month operating expenses. Sequentially, it rose 34.2% from the prior quarter. Over 3 fiscal years it compounded at +75.4% a year.
Context
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +68.4% holds above the trailing-twelve-month pace of +16.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 283.67M USD
- Year-over-year change
- +79.3%
- 4-year CAGR
- +65.6%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 283.67M | +79.3% |
| FY2024 | 2024-12-31 | 158.23M | +54.0% |
| FY2023 | 2023-12-31 | 102.78M | +95.5% |
| FY2022 | 2022-12-31 | 52.56M | +39.4% |
| FY2021 | 2021-12-31 | 37.7M | — |
Operating Expenses vs competitors
How GPCR compares with its peers on the latest reported figures
- GPCR's LTM Jun 2026 operating expenses of $256.85M is the 2nd highest of the 8 companies compared; the peer median is $152.46M.
- Its year-over-year change of +16.9% is the 6th highest of 7, against a peer median of +46.8%.
- Over three fiscal years its annual growth of +75.4% compares with a peer median of +10.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $370.78M | +82.6% | +75.7% | — | |
| LTM Jun 2026 | $256.85M | +16.9% | +75.4% | — | |
SEPNSepterna, Inc. | LTM Sep 2026 | $169.24M | +70.9% | — | 175.8% |
KLRAKailera Therapeutics, Inc. | FY2025 | $158.34M | — | — | — |
| LTM Mar 2026 | $152.46M | +30.0% | +8.2% | 762.3% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $111.96M | +34.4% | +36.6% | 1085.3% |
| LTM Mar 2026 | $65.98M | -50.3% | -1.5% | — | |
| LTM Mar 2026 | $39.88M | +59.2% | +10.1% | 108.3% | |
| Peer median (excluding GPCR) | $152.46M | +46.8% | +10.1% | 469.0% | |
Competitors are the stored peer set for GPCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 3.9M |
| Gross Profit | 0 | 0 | 0 | 0 | (3.9M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 29.11M | 36.19M | 70.1M | 108.81M | 225.26M |
| Selling, General & Admin | 8.59M | 16.37M | 32.67M | 49.41M | 61.55M |
| Operating Expenses | 37.7M | 52.56M | 102.78M | 158.23M | 283.67M |
| Depreciation & Amortization | 72K | 277K | 295K | 992K | 3.9M |
| EBITDA | (37.62M) | (51.03M) | (75.7M) | (121.22M) | (136.79M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (37.7M) | (52.56M) | (102.78M) | (158.23M) | (287.57M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 122 | 1.26M | 13.38M | 36.03M | 35.97M |
| Interest Expense | 122.16K | 0 | 13.39M | 0 | 0 |
| Other Income / Expenses | (122K) | 1.26M | 13.39M | 36.01M | 146.51M |
| Income Before Tax | (37.82M) | (51.3M) | (89.38M) | (122.22M) | (140.69M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 231K | 17K | 236K | 310K | 515K |
| Net Income | (40.01M) | (51.32M) | (89.62M) | (122.53M) | (141.2M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.20) | (1.44) | (2.43) | (2.34) | (2.40) |
| EPS (Diluted) | (1.20) | (1.44) | (2.43) | (2.34) | (2.40) |
| Weighted Avg Shares | 36.59M | 36.59M | 36.73M | 52.64M | 59.2M |
| Weighted Avg Shares (Diluted) | 36.59M | 36.59M | 36.73M | 52.64M | 59.2M |
Structure Therapeutics Inc.
NASDAQ:GPCR
Intrinsic Alpha fair value
Locked
Current Price
$17.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.